1f3202bb-44a5-4bfa-9857-d67faba1c8f1.pdf

REGULATED INFORMATION

PUBLICATION IN ACCORDANCE WITH ARTICLE 15 OF THE BELGIAN LAW OF 2 MAY 2007 ON THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW") GHENT, Belgium, 10 June 2016 - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, as a result of the closing of its private placement which raised €74.2 million on 1 June 2016, the following information in accordance with article 15 of the Law of 2 May 2007 on the publication of major shareholdings in issuers whose shares are admitted to trading on a regulated market (the "Transparency Law").

As of today, Ablynx's total share capital amounts to 113,771,789.41. The total number of securities conferring voting rights is 60,870,926 which is also the total number of voting rights (the "denominator"). The total number of rights (warrants) to subscribe to not yet issued securities conferring voting rights is 2,672,222 which equals the total number of voting rights that may result from the exercise of these warrants. Currently 1,000 convertible bonds are outstanding entitling the holders thereof to 7,733,952 shares of the Company in the aggregate, upon conversion of such convertible bonds.

Total amount of share capital

€113,771,789.41

Total number of securities conferring voting rights

60,870,926

Total number of voting rights (denominator)

60,870,926

Total number of warrants, in number of shares

2,672,222

Maximum additional number of shares after conversion of bonds

7,733,952

Total number of diluted shares

71,277,100

About Ablynx

Ablynx is a biopharmaceutical company engaged in the development of Nanobodies®, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than 40 proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie, Boehringer Ingelheim, Eddingpharm, Genzyme, Merck & Co, Inc., Merck Serono, Novartis and Novo Nordisk. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.

For more information, please contact:

Ablynx:

Dr Edwin Moses CEO

t: +32 (0)9 262 00 07

m: +32 (0)473 39 50 68

e: edwin.moses@ablynx.com

Marieke Vermeersch

Associate Director Investor Relations t: +32 (0)9 262 00 82

m: +32 (0)479 49 06 03

e: marieke.vermeersch@ablynx.com@AblynxABLX

Ablynx media/analyst relations FTI consulting:

Julia Philips, Brett Pollard, Mo Noonan, Matthew Moss t: +44 (0) 203 727 1419

e: ablynx@fticonsulting.com

Disclaimer

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors' current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its parent or subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

Ablynx NV published this content on 10 June 2016 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 14 June 2016 11:04:08 UTC.

Original documenthttp://hugin.info/137912/R/2019623/749870.pdf

Public permalinkhttp://www.publicnow.com/view/392FBCC3CDEA9012CE0C8EFB677A5CACCC21D57C